ALW-II-41-27 is a potent Eph receptor tyrosine kinase inhibitor with IC50 of 11 nM for Eph2.The inhibition of EPHA2 by ALW-II-41-27 decreased both survival and proliferation of erlotinib-resistant tumor cells and inhibited tumor growth in vivo. ALW-II-41-27 was also effective in decreasing viability of cells with acquired resistance to the third-generation EGFR TKI AZD9291. Collectively, these data define a role for EPHA2 in the maintenance of cell survival of TKI-resistant, EGFR-mutant lung cancer and indicate that EPHA2 may serve as a useful therapeutic target in TKI-resistant tumors.

纯度：≥98%

CAS：1186206-79-0